aid: corsair-pharma
name: Corsair Pharma
description: 'Corsair Pharma, Inc. is a privately held clinical-stage biopharmaceutical
  company developing proprietary prodrugs of treprostinil for the treatment of pulmonary
  arterial hypertension (PAH). Its lead program, the TRX-248 transdermal system, is
  an investigational once-daily patch that delivers an inactive treprostinil prodrug
  across the skin for conversion to active drug in the liver, aiming to combine the
  efficacy and titration profile of parenteral prostacyclin therapy with non-invasive
  once-daily dosing. The company completed its preclinical program, announced positive
  Phase 1 results for TRX-248 in June 2026, closed a $23M Series B led by New Rhein
  Healthcare Investors, and has entered a strategic collaboration with United Therapeutics
  to advance novel treprostinil prodrugs. Corsair Pharma is a drug developer, not a
  software vendor: its public web presence is a five-page marketing and investor-news
  site with no developer program, API, SDK, or machine-readable specification of any
  kind.'
url: https://raw.githubusercontent.com/api-evangelist/corsair-pharma/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-11'
modified: '2026-08-11'
image: https://static.wixstatic.com/media/eb8f76_be22d65dbdb84f7dbd3bae3f30cf754e~mv2.png
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Life Sciences
- Drug Development
- Clinical Trials
- Pulmonary Arterial Hypertension
- Transdermal Delivery
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/corsair-pharma-domain-security.yml
- type: Website
  url: https://www.corsairpharma.com/
- type: Blog
  url: https://www.corsairpharma.com/news
- type: BlogRSS
  url: https://www.corsairpharma.com/blog-feed.xml
- type: PrivacyPolicy
  url: https://www.corsairpharma.com/privacy-policy
- type: TermsOfService
  url: https://www.corsairpharma.com/terms-of-use
x-enrichment:
  date: '2026-08-11'
  status: minimal
  pass: local-v1
  artifacts_added: 2
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    Corsair Pharma is a clinical-stage drug developer whose entire web presence is a
    five-page Wix marketing site (home, news, team, privacy-policy, terms-of-use) with
    no developer, API, docs or partner section; the live host additionally answers every
    path with a SiteGround "Robot Challenge Screen" (HTTP 202), so the page inventory
    and the absence of any /.well-known document were confirmed from Wayback Machine
    captures instead.
  evidence:
  - url: https://www.corsairpharma.com/
    status: 202
  - url: https://www.corsairpharma.com/openapi.json
    status: 202
  - url: http://web.archive.org/web/2025id_/https://www.corsairpharma.com/developers
    status: 404
  - url: https://web.archive.org/web/20240405094716/https://www.corsairpharma.com/.well-known/security.txt
    status: 404
  - url: https://api.github.com/orgs/corsairpharma
    status: 404
  - url: https://pypi.org/pypi/corsair-pharma/json
    status: 404
  checked: '2026-08-11'